 Pharmacor --
January 2005
 You Need to Know
Will evidence that aggressive low-density
lipoprotein (LDL)-lowering therapy improves outcomes, together with increasingly
stringent lipid targets, drive the use of more-efficacious statins? Will fixed-dose
combination therapies find a niche in the post-myocardial infarction (PMI)
market? Will the new definition of acute myocardial infarction (AMI), introduced
by the American College of Cardiology (ACC) and the European Society of
Cardiology (ESC) in 2000, substantially increase the diagnosed post-myocardial
infarction (PMI) population?
Introduction
Current treatment options for
post-myocardial infarction (PMI) patients significantly improve outcomes by
reducing low-density lipoprotein (LDL) cholesterol, hypertension, and the risk
of further thrombosis, infarction, and heart failure. However, despite a
plethora of effective therapies, many cardiologists consider the mortality and reinfarction
rates in PMI to be unacceptably high; further, treatment rates are currently
suboptimal. A growing body of evidence that early, aggressive pharmacological
intervention improves outcomes, together with emerging therapies to treat lipid
abnormalities not addressed by existing agents and therapies that reverse
atherosclerosis, will increase the value of the PMI market over the next ten
years.
Key Findings
 In 2003, the number of prevalent cases of post-myocardial
infarction (PMI) in the seven major markets under study (United States, France,
Germany, Italy, Spain, United Kingdom, and Japan) approached 22 million. We
expect this population will grow moderately during our study period (2003-2013)
as a result of an aging population in all markets, sedentary lifestyles,
increasing survival after AMI, and improved diagnosis rates. Growth in sales of
agents to treat this condition will be far more robust over this period as therapies
targeting risk factors such as atherosclerosis and low levels of high-density
lipoprotein (HDL) increase sales from $8.2 billion in 2003.
Agents that can repair damage to the myocardium after an AMI
remain the greatest unmet need in PMI care. Although currently used agents can
retard disease progression and improve cardiac function, they cannot revascularize
ischemic myocardium.
Statins currently dominate the PMI market, backed by robust
efficacy data in secondary prevention. Agents in development that specifically
reverse the atherosclerotic process will add significant value to the PMI
market in the second half of our forecast period.
Why Buy This Report?
Explore market dynamics of the statin class in this secondary
prevention population.
Discover how therapies specifically targeting atherosclerosis
will add value to this market.
Discover how HDL-modifying agents will fare in the clinic and the
marketplace.
|
